Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C154552
http://purl.obolibrary.org/obo/NCIT_C154552
|
|---|---|
| Preferred Name | Gentuximab |
| Definitions |
A recombinant, humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR-2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous injection, gentuximab specifically binds to VEGFR-2, preventing the binding of its ligand, vascular endothelial growth factor (VEGF). Inhibition of VEGFR-2 signaling may potentially inhibit tumor angiogenesis and decrease nutrient supply to tumor cells, resulting in tumor cell death. VEGFR-2 is a type V receptor tyrosine kinase (RTK) expressed on endothelial cells and some tumor cells that regulates endothelial migration and proliferation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant, humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR-2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous injection, gentuximab specifically binds to VEGFR-2, preventing the binding of its ligand, vascular endothelial growth factor (VEGF). Inhibition of VEGFR-2 signaling may potentially inhibit tumor angiogenesis and decrease nutrient supply to tumor cells, resulting in tumor cell death. VEGFR-2 is a type V receptor tyrosine kinase (RTK) expressed on endothelial cells and some tumor cells that regulates endothelial migration and proliferation. |
|---|---|
| prefLabel | Gentuximab
|
| label | Gentuximab
|
| NCI_META_CUI | CL555348
|
| PDQ_Closed_Trial_Search_ID | 794351
|
| code | C154552
|
| prefixIRI | NCIT:C154552
|
| in_subset | |
| Preferred_Name | Gentuximab
|
| Maps_To | Gentuximab
|
| NCI_Drug_Dictionary_ID | 794351
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 794351
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |